| (1R)-AZD-1480 |
|
|
|
|
|
97.62% |
| (2R,5S)-Ritlecitinib |
|
|
|
|
|
99.77% |
| (3R,4S)-Tofacitinib |
|
|
|
|
|
99.74% |
| (3S,4R)-Tofacitinib |
|
|
|
|
|
99.80% |
| (3S,4S)-Tofacitinib |
|
|
|
|
|
99.28% |
| (E/Z)-AG490 |
|
|
|
|
|
99.71% |
| (E/Z)-Zotiraciclib |
|
|
|
|
|
99.70% |
| (E/Z)-Zotiraciclib citrate |
|
|
|
|
|
99.83% |
| (E/Z)-Zotiraciclib hydrochloride |
|
|
|
|
|
99.90% |
| (R)-9b |
|
|
|
|
|
99.51% |
| (R)-α7 nAchR-JAK2-STAT3 agonist 1 |
|
|
|
|
|
99.59% |
| (R,R)-VVD-118313 |
|
|
|
|
|
99.34% |
| (Rac)-TUL01101 |
|
|
|
|
|
|
| (S)-Lomedeucitinib |
|
|
|
|
|
99.09% |
| (Z)-LFM-A13 |
|
|
|
|
|
99.80% |
| Pentagalloylglucose |
|
|
|
|
|
99.57% |
| 1,2,3,4-Tetrahydro Staurosporin |
|
|
|
|
|
|
| 2,6-Dichloro-N-(2-(cyclopropanecarboxamido)pyridin-4-yl)benzamide |
|
|
|
|
|
99.80% |
| 2-NP |
|
|
|
|
|
99.55% |
| 25-Deacetylcucurbitacin A |
|
|
|
|
|
|
| Leucrose |
|
|
|
|
|
98.53% |
| 5TTU |
|
|
|
|
|
|
| 6-Demethoxytangeretin |
|
|
|
|
|
99.37% |
| ABBV-712 |
|
|
|
|
|
99.94% |
| Abrocitinib |
|
|
|
|
|
99.26% |
| AC-430 |
|
|
|
|
|
|
| AC-430 hydrobromide |
|
|
|
|
|
99.70% |
| AG490 |
|
|
|
|
|
99.86% |
| AH057 |
|
|
|
|
|
|
| AJI-100 |
|
|
|
|
|
|
| AJI-214 |
|
|
|
|
|
|
| AMG-47a |
|
|
|
|
|
99.19% |
| AMPK-IN-5 |
|
|
|
|
|
|
| anti-TNBC agent-7 |
|
|
|
|
|
|
| Antitumor agent-123 |
|
|
|
|
|
|
| AS2553627 |
|
|
|
|
|
|
| AT9283 |
|
|
|
|
|
99.67% |
| AT9283 lactic acid |
|
|
|
|
|
|
| Atinvicitinib |
|
|
|
|
|
98.62% |
| Atiprimod |
|
|
|
|
|
|
| Atiprimod dimaleate |
|
|
|
|
|
|
| Atiprimod hydrochloride |
|
|
|
|
|
|
| Atopaxar |
|
|
|
|
|
99.87% |
| Atopaxar hydrobromide |
|
|
|
|
|
|
| Atopaxar hydrochloride |
|
|
|
|
|
|
| AUH-6-96 |
|
|
|
|
|
|
| Axltide |
|
|
|
|
|
|
| AZ-3 |
|
|
|
|
|
98.05% |
| AZ960 |
|
|
|
|
|
97.08% |
| AZD-1480 |
|
|
|
|
|
99.74% |
| Bayer-18 |
|
|
|
|
|
|
| BD750 |
|
|
|
|
|
99.02% |
| Benzene hexabromide |
|
|
|
|
|
98.0% |
| BI-1622 |
|
|
|
|
|
98.02% |
| Blovacitinib |
|
|
|
|
|
99.71% |
| BMS-066 |
|
|
|
|
|
99.09% |
| BMS-911543 |
|
|
|
|
|
98.23% |
| BMS-986202 |
|
|
|
|
|
99.29% |
| BPC 157 |
|
|
|
|
|
99.74% |
| BPC 157 acetate |
|
|
|
|
|
99.78% |
| BRD4-IN-41 |
|
|
|
|
|
|
| Brepocitinib |
|
|
|
|
|
99.97% |
| Brepocitinib P-Tosylate |
|
|
|
|
|
99.99% |
| Brevilin A |
|
|
|
|
|
99.86% |
| Broussonin E |
|
|
|
|
|
98.11% |
| Butyzamide |
|
|
|
|
|
99.83% |
| Butyzamide |
|
|
|
|
|
|
| BVB808 |
|
|
|
|
|
|
| Cadefrecitinib |
|
|
|
|
|
99.81% |
| Calenduloside E |
|
|
|
|
|
99.07% |
| CAY10526 |
|
|
|
|
|
99.12% |
| CEE321 |
|
|
|
|
|
|
| Cenacitinib |
|
|
|
|
|
98.08% |
| CEP-33779 |
|
|
|
|
|
99.12% |
| Cerdulatinib |
|
|
|
|
|
99.06% |
| Cerdulatinib hydrochloride |
|
|
|
|
|
98.96% |
| Cernuumolide J |
|
|
|
|
|
|
| CHZ868 |
|
|
|
|
|
98.69% |
| Coumermycin A1 |
|
|
|
|
|
99.86% |
| CP-352664 |
|
|
|
|
|
|
| CP-690550A |
|
|
|
|
|
|
| CS12192 |
|
|
|
|
|
|
| CT-1 |
|
|
|
|
|
99.90% |
| Cyclanoline chloride |
|
|
|
|
|
96.27% |
| DCZ3301 |
|
|
|
|
|
99.73% |
| Debio 0617B |
|
|
|
|
|
|
| Decernotinib |
|
|
|
|
|
99.91% |
| DEL1187-126-28-16 |
|
|
|
|
|
|
| DEL1187-126-5-80 |
|
|
|
|
|
|
| Demethylasterriquinone B1 |
|
|
|
|
|
98.10% |
| Deucravacitinib |
|
|
|
|
|
99.93% |
| Deucravacitinib analog 1 |
|
|
|
|
|
|
| Deucravacitinib hydrochloride |
|
|
|
|
|
|
| Deucravacitinib-13C,d3 |
|
|
|
|
|
|
| Dimethyl biphenyl-4,4'-dicarboxylate |
|
|
|
|
|
99.85% |
| DPP |
|
|
|
|
|
|
| DPPY |
|
|
|
|
|
|
| DTP3 |
|
|
|
|
|
98.45% |
| Dual Cathepsin L/JAK-IN-1 |
|
|
|
|
|
98.47% |
| EC-70124 |
|
|
|
|
|
|
| EGFR-IN-178 |
|
|
|
|
|
|
| Envudeucitinibum |
|
|
|
|
|
99.56% |
| EP009 |
|
|
|
|
|
|
| FAK-IN-22 |
|
|
|
|
|
|
| Fedratinib |
|
|
|
|
|
99.83% |
| Fedratinib hydrochloride hydrate |
|
|
|
|
|
99.92% |
| Fedratinib-d9 |
|
|
|
|
|
|
| Filgotinib |
|
|
|
|
|
99.77% |
| Filgotinib maleate |
|
|
|
|
|
99.88% |
| Filgotinib-d4 |
|
|
|
|
|
|
| FLLL32 |
|
|
|
|
|
99.41% |
| Flonoltinib |
|
|
|
|
|
99.48% |
| Flonoltinib monomaleate |
|
|
|
|
|
|
| Flonoltinib sulfate |
|
|
|
|
|
|
| Flonoltinib TFA |
|
|
|
|
|
98.04% |
| FLT3/JAK2/BRD4 ligand-1 |
|
|
|
|
|
|
| FM-381 |
|
|
|
|
|
98.08% |
| FM-479 |
|
|
|
|
|
99.2% |
| Fosifidancitinib |
|
|
|
|
|
|
| Frevecitinib |
|
|
|
|
|
99.42% |
| G5-7 |
|
|
|
|
|
98.45% |
| Gamma-glutamylcysteine ammonium |
|
|
|
|
|
|
| Gandotinib |
|
|
|
|
|
99.86% |
| GDC-4379 |
|
|
|
|
|
98.23% |
| GDC-9918 |
|
|
|
|
|
|
| GLPG0634 analog |
|
|
|
|
|
98.07% |
| Glucocorticoid receptor/IL-6-IN-1 |
|
|
|
|
|
|
| GMB-475 |
|
|
|
|
|
98.69% |
| Golidocitinib |
|
|
|
|
|
99.54% |
| Golidocitinib (Standard) |
|
|
|
|
|
|
| GS-829845 |
|
|
|
|
|
99.19% |
| GSK2646264 |
|
|
|
|
|
99.74% |
| Gusacitinib |
|
|
|
|
|
99.63% |
| Gusacitinib hydrochloride |
|
|
|
|
|
|
| Gusacitinib-d4 |
|
|
|
|
|
|
| HAT-SIL-TG-1&AT |
|
|
|
|
|
|
| HD-2a |
|
|
|
|
|
|
| HDAC/JAK/BRD4-IN-1 |
|
|
|
|
|
|
| HG-7-85-01 |
|
|
|
|
|
98.14% |
| Hispidin |
|
|
|
|
|
99.85% |
| iBFAR2 |
|
|
|
|
|
97.24% |
| Icariside I |
|
|
|
|
|
98.76% |
| Ifidancitinib |
|
|
|
|
|
98.01% |
| iJak-381 |
|
|
|
|
|
99.86% |
| Ilginatinib |
|
|
|
|
|
99.81% |
| Ilginatinib hydrochloride |
|
|
|
|
|
98.92% |
| Ilginatinib maleate |
|
|
|
|
|
99.33% |
| Ilunocitinib |
|
|
|
|
|
98.24% |
| INCB16562 |
|
|
|
|
|
|
| IRAK4 modulator-2 |
|
|
|
|
|
99.86% |
| Iridin |
|
|
|
|
|
99.72% |
| Isocryptotanshinone |
|
|
|
|
|
98% |
| Itacitinib |
|
|
|
|
|
99.97% |
| Itacitinib adipate |
|
|
|
|
|
99.18% |
| Itacnosertib |
|
|
|
|
|
99.06% |
| Itacnosertib hydrochloride |
|
|
|
|
|
99.43% |
| Ivarmacitinib |
|
|
|
|
|
99.62% |
| Ivarmacitinib sulfate |
|
|
|
|
|
|
| Izencitinib |
|
|
|
|
|
99.47% |
| JAK 3i |
|
|
|
|
|
99.81% |
| JAK kinase-IN-1 |
|
|
|
|
|
|
| JAK-2/3-IN-1 |
|
|
|
|
|
|
| JAK-2/3-IN-2 |
|
|
|
|
|
|
| JAK-2/3-IN-3 |
|
|
|
|
|
|
| JAK-IN-1 |
|
|
|
|
|
98.39% |
| JAK-IN-10 |
|
|
|
|
|
99.72% |
| JAK-IN-11 |
|
|
|
|
|
98.62% |
| JAK-IN-14 |
|
|
|
|
|
99.15% |
| JAK-IN-15 |
|
|
|
|
|
|
| JAK-IN-17 |
|
|
|
|
|
|
| JAK-IN-18 |
|
|
|
|
|
|
| JAK-IN-19 |
|
|
|
|
|
|
| JAK-IN-20 |
|
|
|
|
|
99.63% |
| JAK-IN-21 |
|
|
|
|
|
99.72% |
| JAK-IN-23 |
|
|
|
|
|
98.88% |
| JAK-IN-24 |
|
|
|
|
|
99.27% |
| JAK-IN-26 |
|
|
|
|
|
98.00% |
| JAK-IN-27 |
|
|
|
|
|
|
| JAK-IN-28 |
|
|
|
|
|
|
| JAK-IN-29 |
|
|
|
|
|
|
| JAK-IN-3 |
|
|
|
|
|
98.92% |
| JAK-IN-30 |
|
|
|
|
|
|
| JAK-IN-31 |
|
|
|
|
|
|
| JAK-IN-32 |
|
|
|
|
|
96.18% |
| JAK-IN-33 |
|
|
|
|
|
|
| JAK-IN-34 |
|
|
|
|
|
|
| JAK-IN-35 |
|
|
|
|
|
99.30% |
| JAK-IN-36 |
|
|
|
|
|
|
| JAK-IN-37 |
|
|
|
|
|
|
| JAK-IN-38 |
|
|
|
|
|
|
| JAK-IN-39 |
|
|
|
|
|
|
| JAK-IN-4 |
|
|
|
|
|
|
| JAK-IN-40 |
|
|
|
|
|
|
| JAK-IN-41 |
|
|
|
|
|
|
| JAK-IN-5 |
|
|
|
|
|
|
| JAK-IN-5 hydrochloride |
|
|
|
|
|
99.52% |
| JAK-STAT-IN-1 |
|
|
|
|
|
|
| JAK/HDAC-IN-1 |
|
|
|
|
|
98.63% |
| JAK/HDAC-IN-2 |
|
|
|
|
|
|
| JAK/HDAC-IN-3 |
|
|
|
|
|
|
| JAK/HDAC-IN-4 |
|
|
|
|
|
|
| JAK1 Human Pre-designed siRNA Set A |
|
|
|
|
|
|
| Jak1 Rat Pre-designed siRNA Set A |
|
|
|
|
|
|
| JAK1 S729C Recombinant Human Active Protein Kinase |
|
|
|
|
|
|
| JAK1(JH1) Recombinant Human Active Protein Kinase |
|
|
|
|
|
|
| JAK1-IN-10 |
|
|
|
|
|
|
| JAK1-IN-11 |
|
|
|
|
|
98.27% |
| JAK1-IN-12 |
|
|
|
|
|
|
| JAK1-IN-13 |
|
|
|
|
|
98.65% |
| JAK1-IN-14 |
|
|
|
|
|
|
| JAK1-IN-16 |
|
|
|
|
|
|
| JAK1-IN-17 |
|
|
|
|
|
|
| JAK1-IN-18 |
|
|
|
|
|
|
| JAK1-IN-19 |
|
|
|
|
|
|
| JAK1-IN-20 |
|
|
|
|
|
|
| JAK1-IN-4 |
|
|
|
|
|
99.26% |
| JAK1-IN-8 |
|
|
|
|
|
95.0% |
| JAK1-IN-9 |
|
|
|
|
|
|
| JAK1/2 ligand 1 |
|
|
|
|
|
99.91% |
| JAK1/2-IN-1 |
|
|
|
|
|
98.36% |
| JAK1/2-IN-2 |
|
|
|
|
|
|
| JAK1/2-IN-3 |
|
|
|
|
|
|
| JAK1/3-IN-1 |
|
|
|
|
|
|
| JAK1/CDK7-IN-1 |
|
|
|
|
|
|
| JAK1/STAT3-IN-1 |
|
|
|
|
|
|
| JAK1/TYK2-IN-1 |
|
|
|
|
|
|
| JAK1/TYK2-IN-3 |
|
|
|
|
|
|
| JAK1/TYK2-IN-4 |
|
|
|
|
|
|
| JAK1/TYK2-IN-5 |
|
|
|
|
|
|
| JAK2 Human Pre-designed siRNA Set A |
|
|
|
|
|
|
| JAK2 JH2 binder-1 |
|
|
|
|
|
95.40% |
| JAK2 JH2 Tracer |
|
|
|
|
|
98.03% |
| Jak2 Mouse Pre-designed siRNA Set A |
|
|
|
|
|
|
| Jak2 Rat Pre-designed siRNA Set A |
|
|
|
|
|
|
| JAK2(JH1/JH2) Recombinant Human Active Protein Kinase |
|
|
|
|
|
|
| JAK2-IN-1 |
|
|
|
|
|
|
| JAK2-IN-10 |
|
|
|
|
|
97.97% |
| JAK2-IN-11 |
|
|
|
|
|
98.03% |
| JAK2-IN-12 |
|
|
|
|
|
|
| JAK2-IN-13 |
|
|
|
|
|
|
| JAK2-IN-14 |
|
|
|
|
|
|
| JAK2-IN-15 |
|
|
|
|
|
|
| JAK2-IN-16 |
|
|
|
|
|
|
| JAK2-IN-17 |
|
|
|
|
|
|
| JAK2-IN-18 |
|
|
|
|
|
|
| JAK2-IN-19 |
|
|
|
|
|
|
| JAK2-IN-20 |
|
|
|
|
|
|
| JAK2-IN-21 |
|
|
|
|
|
|
| JAK2-IN-4 |
|
|
|
|
|
|
| JAK2-IN-5 |
|
|
|
|
|
|
| JAK2-IN-6 |
|
|
|
|
|
97.07% |
| JAK2-IN-7 |
|
|
|
|
|
98.31% |
| JAK2-IN-9 |
|
|
|
|
|
|
| JAK2/FLT3-IN-3 |
|
|
|
|
|
|
| JAK2/STAT3-IN-2 |
|
|
|
|
|
|
| JAK2/TYK2-IN-1 |
|
|
|
|
|
99.94% |
| JAK3 covalent inhibitor-1 |
|
|
|
|
|
|
| JAK3 covalent inhibitor-2 |
|
|
|
|
|
|
| JAK3 Human Pre-designed siRNA Set A |
|
|
|
|
|
|
| Jak3 Mouse Pre-designed siRNA Set A |
|
|
|
|
|
|
| Jak3 Rat Pre-designed siRNA Set A |
|
|
|
|
|
|
| JAK3(JH1) Recombinant Human Active Protein Kinase |
|
|
|
|
|
|
| JAK3-IN-1 |
|
|
|
|
|
99.31% |
| JAK3-IN-11 |
|
|
|
|
|
|
| JAK3-IN-12 |
|
|
|
|
|
|
| JAK3-IN-14 |
|
|
|
|
|
99.32% |
| JAK3-IN-15 |
|
|
|
|
|
|
| JAK3-IN-16 |
|
|
|
|
|
|
| JAK3-IN-17 |
|
|
|
|
|
|
| JAK3-IN-18 |
|
|
|
|
|
|
| JAK3-IN-19 |
|
|
|
|
|
|
| JAK3-IN-20 |
|
|
|
|
|
|
| JAK3-IN-6 |
|
|
|
|
|
99.48% |
| JAK3-IN-7 |
|
|
|
|
|
|
| JAK3-IN-9 |
|
|
|
|
|
|
| JAK3/BTK-IN-1 |
|
|
|
|
|
|
| JAK3/BTK-IN-2 |
|
|
|
|
|
|
| JAK3/BTK-IN-3 |
|
|
|
|
|
|
| JAK3/BTK-IN-4 |
|
|
|
|
|
|
| JAK3/BTK-IN-5 |
|
|
|
|
|
|
| JAK3/BTK-IN-6 |
|
|
|
|
|
|
| JAK3/BTK-IN-7 |
|
|
|
|
|
|
| Jak3tide |
|
|
|
|
|
|
| JANEX-1 |
|
|
|
|
|
99.63% |
| JANEX-1 hydrochloride |
|
|
|
|
|
|
| JI6 |
|
|
|
|
|
|
| JNK-IN-17 |
|
|
|
|
|
|
| JNN-5 |
|
|
|
|
|
|
| K882 |
|
|
|
|
|
|
| LCC-12 formate |
|
|
|
|
|
99.90% |
| Lepzacitinib |
|
|
|
|
|
99.30% |
| LFM-A13 |
|
|
|
|
|
99.65% |
| Liensinine perchlorate |
|
|
|
|
|
99.67% |
| lirucitinib |
|
|
|
|
|
98.72% |
| LNK01004 |
|
|
|
|
|
|
| Lomedeucitinib |
|
|
|
|
|
99.75% |
| Londamocitinib |
|
|
|
|
|
99.79% |
| Lorpucitinib |
|
|
|
|
|
99.95% |
| LRRK2-IN-8 |
|
|
|
|
|
|
| LRRK2/NUAK1/TYK2-IN-1 |
|
|
|
|
|
|
| LS-104 |
|
|
|
|
|
|
| M351-0056 |
|
|
|
|
|
99.48% |
| Mal-PEG4-NPV-PABC-DMEDA-tofacitinib |
|
|
|
|
|
|
| Methionyl-methionine |
|
|
|
|
|
|
| Methyl 6-(1-(4-methoxybenzyl)-1H-pyrazol-4-yl)-4-oxo-4,5-dihydropyrazolo[1,5-a]pyrazine-2-carboxylate |
|
|
|
|
|
98.01% |
| Milpecitinib |
|
|
|
|
|
|
| MJ04 |
|
|
|
|
|
98.08% |
| MLS-2384 free base |
|
|
|
|
|
|
| MMT3-72 |
|
|
|
|
|
|
| MMT3-72-M2 |
|
|
|
|
|
|
| Mocravimod |
|
|
|
|
|
98.39% |
| Mocravimod hydrochloride |
|
|
|
|
|
99.99% |
| Modzatinib |
|
|
|
|
|
|
| Momelotinib |
|
|
|
|
|
98.73% |
| Momelotinib mesylate |
|
|
|
|
|
|
| Momelotinib sulfate |
|
|
|
|
|
98.45% |
| Momelotinib-d4 dihydrochloride hydrate |
|
|
|
|
|
|
| MPT0B098 |
|
|
|
|
|
|
| MRC-G-001 |
|
|
|
|
|
|
| MS-1020 |
|
|
|
|
|
|
| MTP |
|
|
|
|
|
|
| Mulberrofuran G |
|
|
|
|
|
97.86% |
| N-(3-Aminopropyl)cyclohexylamine |
|
|
|
|
|
98.80% |
| Nezulcitinib |
|
|
|
|
|
|
| Nimucitinib |
|
|
|
|
|
99.27% |
| NMS-P953 |
|
|
|
|
|
|
| Nomelcitinib |
|
|
|
|
|
|
| NSC 33994 |
|
|
|
|
|
|
| NSC 42834 |
|
|
|
|
|
96.85% |
| NSC114792 |
|
|
|
|
|
|
| NUAK1-IN-3 |
|
|
|
|
|
|
| NVP-BSK805 |
|
|
|
|
|
99.30% |
| NVP-BSK805 dihydrochloride |
|
|
|
|
|
99.04% |
| NVP-BSK805 trihydrochloride |
|
|
|
|
|
|
| NVP-BVB808 |
|
|
|
|
|
|
| Oclacitinib |
|
|
|
|
|
99.03% |
| Officinalisinin I |
|
|
|
|
|
99.80% |
| oJak-989 |
|
|
|
|
|
|
| ON044580 |
|
|
|
|
|
99.11% |
| Osunprotafib |
|
|
|
|
|
99.38% |
| Ovalicin |
|
|
|
|
|
|
| Pacritinib |
|
|
|
|
|
99.88% |
| Pacritinib citrate |
|
|
|
|
|
99.68% |
| Pacritinib hydrochloride |
|
|
|
|
|
|
| Pacritinib-d4 |
|
|
|
|
|
98.42% |
| Paeoniflorin-6′-O-benzene sulfonate |
|
|
|
|
|
|
| Patiromer |
|
|
|
|
|
95.0% |
| Peficitinib hydrobromide |
|
|
|
|
|
|
| Pentadecanoic acid |
|
|
|
|
|
99.92% |
| PF-00956980 |
|
|
|
|
|
|
| PF-06263276 |
|
|
|
|
|
98.26% |
| PF-1367550 |
|
|
|
|
|
|
| PHI-501 |
|
|
|
|
|
|
| Physalin A |
|
|
|
|
|
99.63% |
| PI3K/Akt/mTOR-IN-7 |
|
|
|
|
|
|
| PJ27 |
|
|
|
|
|
|
| pJAK2(1001-1013) |
|
|
|
|
|
99.89% |
| Povorcitinib |
|
|
|
|
|
99.00% |
| Povorcitinib phosphate |
|
|
|
|
|
98.82% |
| Povorcitinib-d6 |
|
|
|
|
|
|
| PRN-371 |
|
|
|
|
|
|
| PROTAC FLT3/JAK2/BRD4 Degrader-1 |
|
|
|
|
|
|
| PROTAC JAK1 degrader 1 |
|
|
|
|
|
99.97% |
| PROTAC JAK1/2 degrader-1 |
|
|
|
|
|
99.47% |
| PROTAC JAK2 degrader-1 |
|
|
|
|
|
|
| PROTAC SKP2 Degrader-1 |
|
|
|
|
|
99.91% |
| PROTAC TYK2 degrader-1 |
|
|
|
|
|
99.46% |
| PROTAC TYK2 degrader-2 |
|
|
|
|
|
99.50% |
| PTPN2-IN-2 |
|
|
|
|
|
|
| PTPN2/1-IN-4 |
|
|
|
|
|
|
| Pumecitinib |
|
|
|
|
|
99.81% |
| Quecitinib |
|
|
|
|
|
99.56% |
| R-348 choline |
|
|
|
|
|
|
| RAI-20 |
|
|
|
|
|
98.66% |
| RGB-286638 |
|
|
|
|
|
99.67% |
| RGB-286638 free base |
|
|
|
|
|
98.09% |
| Ritlecitinib |
|
|
|
|
|
99.63% |
| Ritlecitinib malonate |
|
|
|
|
|
|
| Ritlecitinib tosylate |
|
|
|
|
|
99.65% |
| RO495 |
|
|
|
|
|
98.59% |
| RO8191 |
|
|
|
|
|
98.80% |
| S6K1-IN-1 |
|
|
|
|
|
99.71% |
| SAR-20347 |
|
|
|
|
|
97.27% |
| SB1578 |
|
|
|
|
|
|
| SC99 |
|
|
|
|
|
98.90% |
| SD-1008 |
|
|
|
|
|
99.10% |
| SD-1029 |
|
|
|
|
|
88.8% |
| SG3-179 |
|
|
|
|
|
|
| SHP2 inhibitor LY6 |
|
|
|
|
|
|
| SIRT5-IN-10 |
|
|
|
|
|
|
| SJ1008030 |
|
|
|
|
|
|
| SJ1008030 formic |
|
|
|
|
|
98.91% |
| SJ1008030 TFA |
|
|
|
|
|
98.12% |
| SJ10542 |
|
|
|
|
|
99.32% |
| SJ988497 |
|
|
|
|
|
99.03% |
| Socrodeucitinib |
|
|
|
|
|
|
| Soficitinib |
|
|
|
|
|
|
| STAT3-IN-18 |
|
|
|
|
|
|
| STAT3-IN-46 |
|
|
|
|
|
|
| STS-E412 |
|
|
|
|
|
98.56% |
| SYK/JAK-IN-1 |
|
|
|
|
|
|
| TCJL37 |
|
|
|
|
|
99.89% |
| TCS 21311 |
|
|
|
|
|
99.49% |
| Ten01 |
|
|
|
|
|
|
| TG101209 |
|
|
|
|
|
98.13% |
| Thi-DPPY |
|
|
|
|
|
|
| TK4b |
|
|
|
|
|
|
| TK4g |
|
|
|
|
|
|
| Tkip |
|
|
|
|
|
95.16% |
| TM-233 |
|
|
|
|
|
|
| Tofacitinib Prodrug-1 |
|
|
|
|
|
|
| TP1L |
|
|
|
|
|
|
| Tubulin/JAK2-IN-1 |
|
|
|
|
|
99.14% |
| Tubulosine |
|
|
|
|
|
|
| TYD-68 |
|
|
|
|
|
99.54% |
| TYK2 activator-1 |
|
|
|
|
|
|
| TYK2 JH2-IN-1-d3 |
|
|
|
|
|
|
| TYK2 ligand 1 |
|
|
|
|
|
|
| TYK2 ligand 2 |
|
|
|
|
|
|
| TYK2 ligand 3 |
|
|
|
|
|
|
| TYK2 ligand 4 |
|
|
|
|
|
|
| TYK2(JH1) Recombinant Human Active Protein Kinase |
|
|
|
|
|
|
| Tyk2(JH1/JH2) Recombinant Human Active Protein Kinase |
|
|
|
|
|
|
| TYK2(JH2) Recombinant Human Active Protein Kinase |
|
|
|
|
|
|
| Tyk2-IN-10 |
|
|
|
|
|
|
| TYK2-IN-11 |
|
|
|
|
|
|
| TYK2-IN-12 |
|
|
|
|
|
98.81% |
| Tyk2-IN-15 |
|
|
|
|
|
|
| Tyk2-IN-16 |
|
|
|
|
|
|
| Tyk2-IN-17 |
|
|
|
|
|
|
| Tyk2-IN-18 |
|
|
|
|
|
|
| Tyk2-IN-18-d3 |
|
|
|
|
|
|
| Tyk2-IN-18-d5 |
|
|
|
|
|
|
| Tyk2-IN-19 |
|
|
|
|
|
98.62% |
| TyK2-IN-2 |
|
|
|
|
|
99.05% |
| Tyk2-IN-20 |
|
|
|
|
|
|
| TyK2-IN-21-d3 |
|
|
|
|
|
|
| Tyk2-IN-22 |
|
|
|
|
|
|
| Tyk2-IN-22-d3 |
|
|
|
|
|
|
| Tyk2-IN-23 |
|
|
|
|
|
|
| Tyk2-IN-3 |
|
|
|
|
|
|
| Tyk2-IN-5 |
|
|
|
|
|
99.35% |
| Tyk2-IN-7 |
|
|
|
|
|
99.58% |
| Tyk2-IN-8 |
|
|
|
|
|
98.04% |
| Tyk2-IN-9 |
|
|
|
|
|
|
| Tyrosine Protein Kinase JAK 2 (Phospho-Tyr8, 9) |
|
|
|
|
|
|
| UCB9386 |
|
|
|
|
|
99.89% |
| UF010 |
|
|
|
|
|
99.83% |
| UNC1062 |
|
|
|
|
|
98.92% |
| VDR agonist 4 |
|
|
|
|
|
|
| Voderdeucitinib |
|
|
|
|
|
|
| VVD-118313 |
|
|
|
|
|
99.47% |
| WCY-8-67 |
|
|
|
|
|
|
| WCY-8-67 TFA |
|
|
|
|
|
99.40% |
| WHI-P154 |
|
|
|
|
|
98.77% |
| WHI-P97 |
|
|
|
|
|
99.16% |
| WP-1034 |
|
|
|
|
|
|
| WP1066 |
|
|
|
|
|
99.53% |
| WP1193 |
|
|
|
|
|
|
| WWQ-03-012 |
|
|
|
|
|
98.04% |
| WWQ-131 |
|
|
|
|
|
|
| WYE-151650 |
|
|
|
|
|
|
| XL019 |
|
|
|
|
|
99.65% |
| YLIU-4-105-1 |
|
|
|
|
|
99.39% |
| YSY01A |
|
|
|
|
|
|
| YYSW001 |
|
|
|
|
|
|
| Zasocitinib |
|
|
|
|
|
99.24% |
| Zingiberen newsaponin |
|
|
|
|
|
99.68% |
| ZM 449829 |
|
|
|
|
|
99.73% |
| ZM39923 |
|
|
|
|
|
|
| ZM39923 hydrochloride |
|
|
|
|
|
99.84% |
| Zotiraciclib |
|
|
|
|
|
99.88% |
| Zotiraciclib hydrochloride |
|
|
|
|
|
|
| ZT55 |
|
|
|
|
|
99.51% |
| α7 nAchR-JAK2-STAT3 agonist 1 |
|
|
|
|
|
98.51% |
| Gamma-glutamylcysteine |
|
|
|
|
|
98.53% |
| Gamma-glutamylcysteine TFA |
|
|
|
|
|
96.68% |
| Notoginsenoside R2 |
|
|
|
|
|
99.80% |
| Upadacitinib |
|
|
|
|
|
99.98% |
| Upadacitinib-d5 |
|
|
|
|
|
|
| Upadacitinib tartrate tetrahydrate |
|
|
|
|
|
|
| Ginsenoside Rk1 |
|
|
|
|
|
99.37% |
| Curculigoside |
|
|
|
|
|
99.82% |
| Peficitinib |
|
|
|
|
|
99.38% |
| Peficitinib-d3 |
|
|
|
|
|
|
| Clifutinib |
|
|
|
|
|
99.59% |
| Ponicidin |
|
|
|
|
|
99.93% |
| Protosappanin A |
|
|
|
|
|
99.95% |
| Dehydrocrenatidine |
|
|
|
|
|
98.0% |
| Icaritin |
|
|
|
|
|
99.06% |
| Desmethoxyyangonin |
|
|
|
|
|
99.00% |
| Pyridone 6 |
|
|
|
|
|
98.20% |
| Mollugin |
|
|
|
|
|
99.79% |
| Oclacitinib monomaleate |
|
|
|
|
|
99.87% |
| Anumigilimab |
|
|
|
|
|
98.43% |
| Microhelenin C |
|
|
|
|
|
99.55% |
| Jolkinolide B |
|
|
|
|
|
99.65% |
| Jolkinolide B (Standard) |
|
|
|
|
|
|
| Baricitinib-d3 |
|
|
|
|
|
99.0% |
| Baricitinib-d5 |
|
|
|
|
|
98.98% |
| Baricitinib |
|
|
|
|
|
99.93% |
| Isotoosendanin |
|
|
|
|
|
99.51% |
| Tofacitinib |
|
|
|
|
|
99.94% |
| Tofacitinib-13C3 |
|
|
|
|
|
99.77% |
| Tofacitinib-13C3,15N |
|
|
|
|
|
99.57% |
| Tofacitinib metabolite-1 |
|
|
|
|
|
99.59% |
| Tropisetron |
|
|
|
|
|
99.93% |
| Tropisetron-d5 |
|
|
|
|
|
|
| Lestaurtinib |
|
|
|
|
|
99.66% |
| Tofacitinib-d3 citrate |
|
|
|
|
|
99.53% |
| Tofacitinib citrate |
|
|
|
|
|
99.94% |
| Phlorizin |
|
|
|
|
|
99.93% |
| Phlorizin dihydrate |
|
|
|
|
|
98.0% |
| Delphinidin chloride |
|
|
|
|
|
98.0% |
| Swertiamarin |
|
|
|
|
|
99.03% |
| Cycloartenyl ferulate |
|
|
|
|
|
99.15% |
| Reticuline |
|
|
|
|
|
98.89% |
| Pulchinenoside E2 |
|
|
|
|
|
99.28% |
| Atractylenolide I |
|
|
|
|
|
99.98% |
| Peficitinib hydrochloride |
|
|
|
|
|
|
| Baricitinib phosphate |
|
|
|
|
|
99.97% |
| Solcitinib |
|
|
|
|
|
99.51% |
| (Rac)-Ruxolitinib-d9 |
|
|
|
|
|
97.18% |
| Graveoline |
|
|
|
|
|
99.93% |
| Momelotinib dihydrochloride |
|
|
|
|
|
|
| Liensinine |
|
|
|
|
|
99.97% |
| Liensinine Diperchlorate |
|
|
|
|
|
99.96% |
| Cucurbitacin I |
|
|
|
|
|
99.60% |
| Bufothionine |
|
|
|
|
|
|
| Crocin |
|
|
|
|
|
99.30% |
| Raspberry ketone glucoside |
|
|
|
|
|
99.52% |
| Telocinobufagin |
|
|
|
|
|
99.50% |
| Delgocitinib |
|
|
|
|
|
99.61% |
| Delgocitinib ethanolate |
|
|
|
|
|
|
| Wilforine |
|
|
|
|
|
99.47% |
| Radotinib |
|
|
|
|
|
99.19% |
| Radotinib-d6 |
|
|
|
|
|
|
| Radotinib dihydrochloride |
|
|
|
|
|
|
| Fezakinumab |
|
|
|
|
|
99.9% |
| Lentinan |
|
|
|
|
|
|
| Ruxolitinib (S enantiomer) |
|
|
|
|
|
99.64% |
| Deuruxolitinib |
|
|
|
|
|
99.18% |
| Ruxolitinib-d9 |
|
|
|
|
|
|
| Ruxolitinib |
|
|
|
|
|
99.90% |
| Ruxolitinib sulfate |
|
|
|
|
|
|
| Ruxolitinib phosphate |
|
|
|
|
|
99.97% |